VEGF Trap in Treating Patients With Recurrent or Persistent Endometrial Cancer

Inclusion Criteria:

* Histologically confirmed endometrial carcinoma, meeting both of the following criteria:

  * Recurrent or persistent disease
  * Refractory to curative therapy or established treatments
* Measurable disease, defined as ≥ 1 unidimensionally measurable lesion ≥ 20 mm by conventional techniques OR ≥ 10 mm by spiral CT scan

  * Tumors within a previously irradiated field are designated as nontarget lesions unless progression is documented or a biopsy is obtained to confirm persistence at least 90 days after completion of radiotherapy
* Must have received one prior chemotherapeutic regimen for management of endometrial carcinoma (initial treatment may include high-dose therapy, consolidation therapy, or extended therapy administered after surgical or non-surgical assessment)
* Not a candidate for a higher priority GOG protocol
* No history or evidence of primary brain tumor or brain metastases
* GOG performance status (PS) 0-2 (patients who received 1 prior regimen) OR GOG PS 0-1 (patients who received 2 prior regimens)
* Absolute neutrophil count ≥ 1,500/mm\^3
* Platelet count ≥ 100,000/mm\^3
* Urine protein:creatinine ratio \< 1.0 OR urine protein \< 1.0 g by 24-hour urine collection
* Creatinine ≤ 1.5 times upper limit of normal (ULN)
* Bilirubin ≤ 1.5 times ULN
* SGOT ≤ 2.5 times ULN
* Alkaline phosphatase ≤ 2.5 times ULN
* PT/PTT/INR ≤ 1.5 times ULN

  * In-range INR (between 2 and 3) allowed if patient is on a stable dose of therapeutic warfarin
* QTc \< 500 msec
* No evidence of serious ventricular arrhythmia

  * Ventricular tachycardia or ventricular fibrillation must be \< 3 beats in a row
* LVEF normal

  * Ejection fraction ≥ 50% (for patients who received prior anthracycline, including doxorubicin hydrochloride and/or doxorubicin hydrochloride liposome)
* No clinically significant cardiovascular disease, including any of the following:

  * Uncontrolled hypertension, defined as systolic blood pressure (BP) \> 140 mm Hg or diastolic BP \> 90 mm Hg
  * Myocardial infarction or unstable angina within the past 6 months
  * NYHA class II-IV congestive heart failure
  * Serious cardiac arrhythmia requiring medication
  * Peripheral vascular disease ≥ grade 2
  * Cerebrovascular accident (i.e., CVA or stroke), transient ischemic attack, or subarachnoid hemorrhage within the past 6 months
* Not pregnant or nursing
* Negative pregnancy test
* Fertile patients must use effective contraception during and for ≥ 6 months after completion of study therapy
* No HIV positivity
* No neuropathy (sensory and motor) \> grade 1
* No active infection requiring antibiotics
* No other invasive malignancies or any evidence of other cancer within the past 5 years except for nonmelanoma skin cancer
* No serious nonhealing wound, ulcer, or bone fracture
* No history of abdominal fistula or gastrointestinal perforation
* No history or evidence of seizures not controlled with standard medical therapy
* No intra-abdominal abscess within the past 28 days
* No active bleeding or pathologic conditions that carry a high risk of bleeding (e.g., bleeding disorder, coagulopathy, or tumor involving major vessels)
* No known hypersensitivity to Chinese hamster ovary cell products or other recombinant human or humanized antibodies
* No significant traumatic injury within the past 28 days
* No concurrent combination antiretroviral therapy for HIV-positive patients
* Recovered from prior surgery
* More than 3 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin C) or radiotherapy and recovered
* At least 1 week since prior hormonal therapy

  * Concurrent hormone replacement therapy allowed
* At least 3 weeks since any other prior therapy, including immunologic agents
* One additional prior cytotoxic regimen for management of recurrent or persistent endometrial cancer allowed

  * Cytotoxic regimens include any agent that targets the genetic and/or mitotic apparatus of dividing cells, resulting in dose-limiting toxicity to the bone marrow and/or gastrointestinal mucosa
* More than 28 days since prior major surgery or open biopsy
* More than 7 days since prior minor surgery, fine needle aspirates, or core biopsies
* No prior cancer treatment that would preclude study compliance
* No prior noncytotoxic chemotherapy for management of recurrent or persistent endometrial disease
* No prior VEGF Trap or other VEGF pathway-targeted therapy
* More than 5 years since prior radiotherapy to any portion of the abdominal cavity or pelvis except for the treatment of endometrial cancer

  * More than 3 years since prior radiotherapy for localized cancer of the breast, head and neck, or skin

    * Patient must remain free of recurrent or metastatic disease
* More than 5 years since prior chemotherapy for any abdominal or pelvic tumor except for the treatment of endometrial cancer

  * More than 3 years since prior adjuvant chemotherapy for localized breast cancer

    * Patient must remain free of recurrent or metastatic disease
* Concurrent low-molecular weight heparin allowed for the prevention or treatment of venous thromboembolic disease if condition is considered clinically stable with treatment
* No other concurrent investigational agents
* No concurrent major surgery